FDA
-
-
-
-
-
-
-
Biogen (BIIB) Reports Positive CHMP Opinion for QALSODY
-
-
-
-
-
-
-
Biogen to Realign Resources for Alzheimer's Disease Franchise
-
-
-
-
-
-
-
Eisai, Biogen (BIIB) Injectable-At-Home Alzheimer's Drug Demonstrates Encouraging Potential
-
-
-
-
-
-
-
Biogen Completes Acquisition of Reata Pharmaceuticals
-
-
-
-
-
-
-
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
-
-
-
-
-
-
-
Biogen (BIIB) will resume trading at 7:10 AM ET following FDA traditional approval of LEQEMBI
-
-
-
-
-
-
-
Biogen shares jump after FDA advisory panel backs Alzheimer's drug
-
251,776 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All